EchelonDx and Cradle Genomics Join Forces to Accelerate Development of Comprehensive Non-Invasive Prenatal Diagnostic Products
b"Echelon Diagnostics, Inc. , a leading provider of genomic healthcare AI imaging analysis and big data solutions, and Cradle Genomics, Inc. , inventors of a novel prenatal testing methodology, today announced an agreement that will help accelerate the development of Cradle\xe2\x80\x99s innovative cellular-based non-invasive prenatal diagnosic (NIPD) products.
- b"Echelon Diagnostics, Inc. , a leading provider of genomic healthcare AI imaging analysis and big data solutions, and Cradle Genomics, Inc. , inventors of a novel prenatal testing methodology, today announced an agreement that will help accelerate the development of Cradle\xe2\x80\x99s innovative cellular-based non-invasive prenatal diagnosic (NIPD) products.
- Cradle Genomics' proprietary assay technology was designed to overcome this challenge by isolating and utilizing intact cells, which increases the purity of fetal DNA and enables diagnostic testing as early as the fifth week of pregnancy.
- Cradle is developing novel fetal genetic analysis and pregnancy health solutions at the earliest stages of pregnancy.
- Based in Reno, Nevada, the company continues to advance the field of genomics by supporting its growing number of customers around the world.